Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000 Shares Of Newly Created Series C Convertible Preferred Stock With An Aggregate Stated Value Of $12M

Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company") today announced that it has closed its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. ("SOD Sciences" or "SOD") and a 50% undivided co-ownership interest in SOD's pseudohypoxia early‑warning test, the "Primed Cell for Chronic Disease" test. In exchange, Vivos issued to SOD 12,000 shares of newly created Series C Convertible Preferred Stock with an aggregate stated value of $12 million. No cash consideration was paid by either party. Through the joint marketing arrangement to be negotiated with SOD following closing and SOD’s marketing relationship with Florida based CLIA-certified lab American Health Associates ("AHA"), Vivos also expects to obtain the opportunity to test and treat AHA’s more than 325,000 existing patients at approximately 3,000 assisted living facilities and nursing homes, many of whom are believed to be at elevated risk for OSA and for chronic diseases such as diabetes, cancer, and cardiovascular disease, subject to the negotiation and execution of definitive agreements and to final approval of the bankruptcy court in AHA’s pending bankruptcy proceeding.